KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Receivables: 2019-2021

Historic Change in Receivables for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Dec 2021 value amounting to -$114,000.

  • Recursion Pharmaceuticals' Change in Receivables fell 100.05% to -$16,000 in Q3 2021 from the same period last year, while for Sep 2021 it was -$30.2 million, marking a year-over-year change of. This contributed to the annual value of -$114,000 for FY2021, which is 2380.00% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Change in Receivables stood at -$114,000 for FY2021, which was down 2,380.00% from $5,000 recorded in FY2020.
  • Over the past 5 years, Recursion Pharmaceuticals' Change in Receivables peaked at $27,000 during FY2019, and registered a low of -$114,000 during FY2021.
  • For the 3-year period, Recursion Pharmaceuticals' Change in Receivables averaged around -$27,333, with its median value being $5,000 (2020).
  • Data for Recursion Pharmaceuticals' Change in Receivables shows a maximum YoY crashed of 2,380.00% (in 2021) over the last 5 years.
  • Yearly analysis of 3 years shows Recursion Pharmaceuticals' Change in Receivables stood at $27,000 in 2019, then crashed by 81.48% to $5,000 in 2020, then slumped by 2,380.00% to -$114,000 in 2021.